Coronary heart disease: the percentage of patients with a history of myocardial infarction (diagnosed after 1 April 2003) who are currently treated with an angiotensin-converting enzyme (ACE) inhibitor or Angiotensin II antagonist.

Brief Summary

TITLE

SOURCE(S)

British Medical Association (BMA). Quality and outcomes framework guidance. London (UK): British Medical Association (BMA); 2006. 132 p.

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients with a history of myocardial infarction (diagnosed after 1 April 2003) who are currently treated with an angiotensin-converting enzyme (ACE) inhibitor or Angiotensin II antagonist.

RATIONALE

Coronary heart disease (CHD) is the single commonest cause of premature death in the United Kingdom (UK). The research evidence relating to the management of CHD is well established and if implemented can reduce the risk of death from CHD and improve the quality of life for patients. This measure is one of ten Secondary Prevention in Coronary Heart Disease (CHD) measures. The "Secondary Prevention in Coronary Heart Disease (CHD)" indicator set focuses on the management of patients with established CHD consistent with clinical priorities in the four nations.

A number of trials have shown reduced mortality following myocardial infarction with the use of angiotensin-converting enzyme (ACE) inhibitors. The Heart Outcome Prevention Evaluation (HOPE) showed that ACE inhibitors are also of benefit in reducing coronary events and progression of coronary arteriosclerosis in patients without left ventricular systolic dysfunction. There is evidence that angiotensin II antagonists have a similar effect.

Refer to the Scottish Intercollegiate Guidelines Network (SIGN) guideline, "Secondary prevention of coronary heart disease following myocardial infarction" (SIGN Publication No. 41, January 2000) for further information.

PRIMARY CLINICAL COMPONENT

Coronary heart disease; myocardial infarction, angiotensin-converting enzyme (ACE) inhibitor; angiotensin II antagonist

DENOMINATOR DESCRIPTION

Patients with a history of myocardial infarction (diagnosed after 1 April 2003)

NUMERATOR DESCRIPTION

Number of patients from the denominator who are currently treated with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II antagonist*

*Note: ACE inhibitor or angiotensin II antagonist prescribed in the last six months

DATA SOURCE

Medical record
Registry data

Identifying Information

ORIGINAL TITLE

CHD 11. The percentage of patients with a history of myocardial infarction (diagnosed after 1 April 2003) who are currently treated with an ACE inhibitor or Angiotensin II antagonist.

MEASURE COLLECTION

Quality and Outcomes Framework Indicators

MEASURE SET NAME

Secondary Prevention in Coronary Heart Disease (CHD)

DEVELOPER

British Medical Association
National Health System (NHS) Confederation

ENDORSER

National Health Service (NHS)

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2004 Apr

REVISION DATE

2006 Feb

MEASURE STATUS

Please note: This measure has been updated. The National Quality Measures Clearinghouse is working to update this summary.

SOURCE(S)

British Medical Association (BMA). Quality and outcomes framework guidance. London (UK): British Medical Association (BMA); 2006. 132 p.

MEASURE AVAILABILITY

The individual measure, "CHD 11. The percentage of patients with a history of myocardial infarction (diagnosed after 1 April 2003) who are currently treated with an ACE inhibitor or Angiotensin II antagonist," is published in the "Quality and outcomes framework guidance." An update of this document is available in Portable Document Format (PDF) from the British Medical Association Web site.

NQMC STATUS

This NQMC summary was completed by ECRI on September 19, 2006. The information was verified by the measure developer on November 1, 2006.

COPYRIGHT STATEMENT

No copyright restrictions apply.

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

Brief Summary

TITLE

SOURCE(S)

Measure Domain

PRIMARY MEASURE DOMAIN

SECONDARY MEASURE DOMAIN

Brief Abstract

DESCRIPTION

RATIONALE

PRIMARY CLINICAL COMPONENT

DENOMINATOR DESCRIPTION

NUMERATOR DESCRIPTION

DATA SOURCE

Identifying Information

ORIGINAL TITLE

MEASURE COLLECTION

MEASURE SET NAME

DEVELOPER

ENDORSER

ADAPTATION

RELEASE DATE

REVISION DATE

MEASURE STATUS

SOURCE(S)

MEASURE AVAILABILITY

NQMC STATUS

COPYRIGHT STATEMENT

Disclaimer

NQMC DISCLAIMER

Search

Summary

Browse

Compare